4D Molecular Therapeutics (FDMT) Equity Average: 2021-2025
Historic Equity Average for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $394.9 million.
- 4D Molecular Therapeutics' Equity Average fell 30.79% to $394.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.9 million, marking a year-over-year decrease of 30.79%. This contributed to the annual value of $409.2 million for FY2024, which is 51.80% up from last year.
- As of Q3 2025, 4D Molecular Therapeutics' Equity Average stood at $394.9 million, which was down 11.31% from $445.3 million recorded in Q2 2025.
- 4D Molecular Therapeutics' Equity Average's 5-year high stood at $594.5 million during Q2 2024, with a 5-year trough of $225.0 million in Q1 2023.
- Its 3-year average for Equity Average is $420.4 million, with a median of $445.3 million in 2025.
- As far as peak fluctuations go, 4D Molecular Therapeutics' Equity Average soared by 118.65% in 2024, and later tumbled by 30.79% in 2025.
- 4D Molecular Therapeutics' Equity Average (Quarterly) stood at $271.6 million in 2021, then fell by 11.13% to $241.4 million in 2022, then spiked by 32.10% to $318.9 million in 2023, then skyrocketed by 66.76% to $531.8 million in 2024, then slumped by 30.79% to $394.9 million in 2025.
- Its Equity Average stands at $394.9 million for Q3 2025, versus $445.3 million for Q2 2025 and $490.2 million for Q1 2025.